NEAT1 in Bone Marrow Mesenchymal Stem Cell-derived Extracellular Vesicles Promotes Melanoma by Inducing M2 Macrophage Polarization

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2022 Feb 4

PMID 35115683

Authors

Yemei Yang

Shengfang Ma

Zi Ye

Yushi Zheng

Zhenjiong Zheng

Xiongshan Liu

Xianyi Zhou

Affiliations

Soon will be listed here.

Abstract

Bone marrow mesenchymal stem cells (BMSCs)-derived extracellular vesicles (EVs) reportedly play an important role in melanoma pathogenesis. This study aimed to explore the mechanisms of EVs-carried long non-coding RNA (lncRNA) NEAT1 involvement in melanoma. Gain- and loss-of-function experiments were performed to determine biological characteristics of A-375 melanoma cells. Bioinfomatic prediction, RNA immunoprecipitation (RIP), and dual luciferase reporter gene experiments were applied to investigate the roles of NEAT1 and microRNA-374a-5p (miR-374a-5p), and leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4). A subcutaneous tumor model was constructed using nude mice, and in vivo fluorescence imaging was used to observe the effect of NEAT1 on the growth and metastasis of melanoma cells in vivo. The results indicated that BMSC-EVs could be internalized by macrophages to promote the expression of macrophages M2 markers. M2 type macrophages promoted malignancy of melanoma cells. NEAT1 derived from BMSC-EVs promoted the progression of melanoma by promoting M2 polarization of macrophages. NEAT1 inhibits miR-374 expression, while miR-374 could upregulate LGR4-dependent IQGAP1 expression. The tumor-inhibiting effect of NEAT1 silencing was validated in the nude mouse xenograft model. Collectively, the results demonstrated that BMSC-EVs carrying NEAT1 can promote the progression of melanoma by inducing M2 polarization of macrophages, and thus may be considered as a potential target for melanoma therapeutics.

Citing Articles

Unravelling the Regulatory Roles of lncRNAs in Melanoma: From Mechanistic Insights to Target Selection.

Moras B, Sissi C Int J Mol Sci. 2025; 26(5).

PMID: 40076754 PMC: 11900516. DOI: 10.3390/ijms26052126.

The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis.

Guo S, Huang J, Li G, Chen W, Li Z, Lei J Mol Cancer. 2023; 22(1):193.

PMID: 38037077 PMC: 10688140. DOI: 10.1186/s12943-023-01909-5.

The extracellular vesicles targeting tumor microenvironment: a promising therapeutic strategy for melanoma.

Li Y, Liu F Front Immunol. 2023; 14:1200249.

PMID: 37575250 PMC: 10419216. DOI: 10.3389/fimmu.2023.1200249.

miRNAs, Mesenchymal Stromal Cells and Major Neoplastic and Inflammatory Skin Diseases: A Page Being Written: A Systematic Review.

Di Vincenzo M, Diotallevi F, Piccirillo S, Carnevale G, Offidani A, Campanati A Int J Mol Sci. 2023; 24(10).

PMID: 37239847 PMC: 10217999. DOI: 10.3390/ijms24108502.

Extracellular RNA in melanoma: Advances, challenges, and opportunities.

Li Z, Gao Y, Cao Y, He F, Jiang R, Liu H Front Cell Dev Biol. 2023; 11:1141543.

PMID: 37215082 PMC: 10192583. DOI: 10.3389/fcell.2023.1141543.

References

Lin W, Fisher D . Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annu Rev Pathol. 2016; 12:75-102. DOI: 10.1146/annurev-pathol-052016-100208. View

Liu Q, Das M, Liu Y, Huang L . Targeted drug delivery to melanoma. Adv Drug Deliv Rev. 2017; 127:208-221. DOI: 10.1016/j.addr.2017.09.016. View

Arozarena I, Wellbrock C . Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019; 19(7):377-391. DOI: 10.1038/s41568-019-0154-4. View

Kleszczynski K, Kim T, Bilska B, Sarna M, Mokrzynski K, Stegemann A . Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells. J Pineal Res. 2019; 67(4):e12610. PMC: 7924888. DOI: 10.1111/jpi.12610. View

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P . Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol. 2018; 30(2):317-324. PMC: 6386028. DOI: 10.1093/annonc/mdy500. View

Mirzaei H, Salehi H, Kazemi Oskuee R, Mohammadpour A, Mirzaei H, Sharifi M . The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model. Cancer Lett. 2018; 419:30-39. DOI: 10.1016/j.canlet.2018.01.029. View

Davoodvandi A, Darvish M, Borran S, Nejati M, Mazaheri S, Tamtaji O . The therapeutic potential of resveratrol in a mouse model of melanoma lung metastasis. Int Immunopharmacol. 2020; 88:106905. DOI: 10.1016/j.intimp.2020.106905. View

Mardani R, Hamblin M, Taghizadeh M, Banafshe H, Nejati M, Mokhtari M . Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. Pathol Res Pract. 2020; 216(9):153082. DOI: 10.1016/j.prp.2020.153082. View

Jiang S, Mo C, Guo S, Zhuang J, Huang B, Mao X . Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the progression of prostate cancer through suppression of RHPN2. J Exp Clin Cancer Res. 2019; 38(1):495. PMC: 6918609. DOI: 10.1186/s13046-019-1488-1. View

10.

Milman N, Ginini L, Gil Z . Exosomes and their role in tumorigenesis and anticancer drug resistance. Drug Resist Updat. 2019; 45:1-12. DOI: 10.1016/j.drup.2019.07.003. View

11.

Mannavola F, Tucci M, Felici C, Passarelli A, DOronzo S, Silvestris F . Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. J Transl Med. 2019; 17(1):230. PMC: 6642540. DOI: 10.1186/s12967-019-1982-4. View

12.

Zhang P, Lu B, Zhang Q, Xu F, Zhang R, Wang C . LncRNA NEAT1 Sponges MiRNA-148a-3p to Suppress Choroidal Neovascularization and M2 macrophage polarization. Mol Immunol. 2020; 127:212-222. DOI: 10.1016/j.molimm.2020.08.008. View

13.

Bardi G, Smith M, Hood J . Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine. 2018; 105:63-72. PMC: 5857255. DOI: 10.1016/j.cyto.2018.02.002. View

14.

Fathullahzadeh S, Mirzaei H, Honardoost M, Sahebkar A, Salehi M . Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther. 2016; 23(10):327-332. DOI: 10.1038/cgt.2016.34. View

15.

Chen L, Zhou Y, Li H . LncRNA, miRNA and lncRNA-miRNA interaction in viral infection. Virus Res. 2018; 257:25-32. DOI: 10.1016/j.virusres.2018.08.018. View

16.

Zhou Z, Zheng L, Ren X, Li A, Zhou W . LncRNA NEAT1 facilitates survival and angiogenesis in oxygen-glucose deprivation (OGD)-induced brain microvascular endothelial cells (BMECs) via targeting miR-377 and upregulating SIRT1, VEGFA, and BCL-XL. Brain Res. 2018; 1707:90-98. DOI: 10.1016/j.brainres.2018.10.031. View

17.

Nahand J, Shojaie L, Akhlagh S, Ebrahimi M, Mirzaei H, Baghi H . Cell death pathways and viruses: Role of microRNAs. Mol Ther Nucleic Acids. 2021; 24:487-511. PMC: 8056183. DOI: 10.1016/j.omtn.2021.03.011. View

18.

Hashemipour M, Boroumand H, Mollazadeh S, Tajiknia V, Nourollahzadeh Z, Rohani Borj M . Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers. Gynecol Oncol. 2021; 161(1):314-327. DOI: 10.1016/j.ygyno.2021.02.004. View

19.

Mohammadi M, Goodarzi M, Jaafari M, Mirzaei H, Mirzaei H . Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther. 2016; 23(11):371-372. DOI: 10.1038/cgt.2016.45. View

20.

Li X, Li Z, Xu Y, Han Z, Liu Z . microRNA-374 inhibits proliferation and promotes apoptosis of mouse melanoma cells by inactivating the Wnt signalling pathway through its effect on tyrosinase. J Cell Mol Med. 2019; 23(8):4991-5005. PMC: 6653165. DOI: 10.1111/jcmm.14348. View